Innate Immunity and SARS-CoV-2 Vaccine Response in Hemodialysis Patients

Nicolas Valentini; Lorie Marchitto; Maxime Raymond; Guillaume Goyette; Daniel E Kaufmann; Andrés Finzi; Rita S Suri; Caroline Lamarche

doi:10.34067/KID.0002542022

Innate Immunity and SARS-CoV-2 Vaccine Response in Hemodialysis Patients

Kidney360. 2022 Aug 9;3(10):1763-1768. doi: 10.34067/KID.0002542022. eCollection 2022 Oct 27.

Authors

Nicolas Valentini^{1

2}, Lorie Marchitto^{3

4}, Maxime Raymond¹, Guillaume Goyette³, Daniel E Kaufmann^{3

5}, Andrés Finzi^{3

4}, Rita S Suri^{6

7}, Caroline Lamarche^{1

5}

Affiliations

¹ Hôpital Maisonneuve-Rosemont Research Institute, Montreal, Quebec, Canada.
² Department of Pharmacology and Physiology, University of Montreal, Montreal, Quebec, Canada.
³ Centre Hospitalier Universitaire de Montreal (CHUM) Research Institute, Montreal, Quebec, Canada.
⁴ Department of Microbiology, Infectiology and Immunology, University of Montreal, Montreal, Quebec, Canada.
⁵ Departement of Medicine, University of Montreal, Montreal, Quebec, Canada.
⁶ Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
⁷ Department of Medicine, McGill University, Montreal, Quebec, Canada.

Abstract

Patients receiving hemodialysis (HD) have more inflammatory monocytes and less plasmacytoid dendritic cells (DCs) compared with healthy controls.Patients on HD who have a poor antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine had fewer monocyte-derived DCs and conventional DCs compared with good responders.The defects in antigen presentation might be possible therapeutic targets to increase vaccine efficacy in HD patients.

Keywords: COVID-19; SARS-CoV-2; basic science; chronic kidney disease; dendritic cell; immune response; innate immunity; mRNA vaccine; monocyte.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines*
COVID-19* / prevention & control
Humans
Immunity, Innate
Renal Dialysis / adverse effects
SARS-CoV-2

Substances

COVID-19 Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding